REPL: Bull Flag detected on 6 Jul 2026

REPL is forming a bull flag pattern with excellent structural quality (15/15) after rising 30.5% in one month and 52% over three months. The stock closed at $11.58, now testing resistance at $10.00 with strong support at $8.25 (447 basis point swing room). Volume is muted at 81% of average (2.8M vs 3.5M), which is typical for flag consolidation. The 71.94% win probability and 82.4 overall score suggest solid setup quality, though the breakout score of 9.4/13 indicates modest momentum confirmation. RSI at 70.62 shows overbought conditions heading into the breakout attempt.

The FDA accepted the resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma treatment with a goal date of August 2, 2026, and an expected advisory committee meeting in late July. This reversal follows a Complete Response Letter rejection in April 2026 citing insufficient efficacy data, which caused a 67% crash. At ASCO 2026, RP1 plus nivolumab demonstrated 47.8% 3-year survival in anti-PD-1-failed melanoma patients. However, the company reported $319.9M operating expenses and a $313.9M net loss for fiscal year ended March 31, 2026, with cash expected to fund operations through Q1 2027. The approval catalyst is imminent.

A successful bull flag breakout above $10.00 resistance would target $11.96 conservatively, representing a modest 3.3% move from breakout point. Historical biotech flag patterns show completion in 1-3 weeks. Volume confirmation is critical—breakout should see relative volume above 1.0x to signal institutional participation, especially given current 0.81 ratio. Invalidation occurs below $8.25 support, which would signal reversal of the broader recovery trend. With 71.94% win probability, the pattern suggests a 2:1 favorable risk-reward, though the low ATR percentage (8.2%) indicates limited intraday volatility for the move.

Immediate execution risk exists with the FDA advisory committee meeting expected in late July before the August 2 decision date. Approval is not guaranteed despite FDA acceptance—the company must present sufficient evidence to overcome previous objections. After the April CRL, Cantor Fitzgerald and Piper Sandler downgraded REPL to Neutral with a $4 price target, suggesting downside risk if approval falters. The stock is deeply overbought (RSI 70.62) and up 672% from 52-week lows, making it vulnerable to profit-taking. Cash runway ending Q1 2027 raises dilution risk if financing is required. MACD histogram negative (-0.0328) signals weakening momentum despite price strength.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.